Skip to main content

Allogene Therapeutics Inc(ALLO-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of Directors

Globe Newswire - Tue Jul 12, 2022

SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Stephen L. Mayo, Ph.D., a world renowned expert in computational protein design, to the company’s Board of Directors.

Read more at globenewswire.com

Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe